Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there ...
The United States has begun distributing a groundbreaking HIV-prevention treatment to two African nations, marking a ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
AllAfrica on MSN
Uganda Winning HIV Fight but Faces New Threats Among Youth - Uganda Aids Commission Warns
Uganda has recorded major gains against HIV, with significant declines in prevalence, new infections, and AIDS-related deaths, but emerging concerns among young people and persistent mother-to-child ...
Of the 3,185 new HIV cases recorded last year, 4.2% or 135 cases were detected among adolescents aged between 10 and 19, says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback